Literature DB >> 34000224

Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Advanced Cystic Fibrosis Lung Disease.

Amir Reza Djavid1, Alison E Thompson2, Alexandria L Irace1, Elen Gusman3, Kimberly Altman4, Emily A DiMango2, Claire L Keating5.   

Abstract

Entities:  

Year:  2021        PMID： 34000224     DOI： 10.1513/AnnalsATS.202102-220RL

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN： 2325-6621


× No keyword cloud information.
  3 in total

1.  Elexacaftor/Tezacaftor/Ivacaftor Improved Clinical Outcomes in a Patient with N1303K-CFTR Based on In Vitro Experimental Evidence.

Authors:  Yunjie Huang; Grace Paul; Jesun Lee; Sunitha Yarlagadda; Karen McCoy; Anjaparavanda P Naren
Journal:  Am J Respir Crit Care Med       Date:  2021-11-15       Impact factor: 30.528

2.  Elexacaftor/Tezacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for the F508del Mutation and Advanced Lung Disease: A 48-Week Observational Study.

Authors:  Vincenzo Carnovale; Paola Iacotucci; Vito Terlizzi; Carmela Colangelo; Lorenza Ferrillo; Angela Pepe; Michela Francalanci; Giovanni Taccetti; Serena Buonaurio; Assunta Celardo; Laura Salvadori; Giovanni Marsicovetere; Michele D'Andria; Nicola Ferrara; Donatello Salvatore
Journal:  J Clin Med       Date:  2022-02-16       Impact factor: 4.241

Review 3.  Left behind: The potential impact of CFTR modulators on racial and ethnic disparities in cystic fibrosis.

Authors:  Meghan E McGarry; Elizabeth R Gibb; Gabriela R Oates; Michael S Schechter
Journal:  Paediatr Respir Rev       Date:  2021-12-22       Impact factor: 5.526
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.